Protein kinase B (AKT1) genotype mediates sensitivity to cannabis-induced impairments in psychomotor control

Psychological Medicine

Volumn 44, Issue 15, 2014, Pages 3315-3328

  Bhattacharyya, S ^a   Iyegbe, C ^a   Atakan, Z ^a   Martin Santos, R ^b   Crippa, J A ^c   Xu, X ^a   Williams, S ^a   Brammer, M ^a   Rubia, K ^a   Prata, D ^a   Collier, D A ^a   McGuire, P K ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

AKT1 gene; functional magnetic resonance imaging; impulsivity; inferior frontal gyrus; response inhibition; 9 tetrahydrocannabinol

Indexed keywords

AKT1 PROTEIN, HUMAN; CANNABINOID RECEPTOR AGONIST; DRONABINOL; PROTEIN KINASE B;

ADULT; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; GENETICS; GENOTYPE; HUMAN; INHIBITION (PSYCHOLOGY); MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY; PREFRONTAL CORTEX; PSYCHOMOTOR PERFORMANCE; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADULT; CANNABINOID RECEPTOR AGONISTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRONABINOL; GENOTYPE; HUMANS; INHIBITION (PSYCHOLOGY); MAGNETIC RESONANCE IMAGING; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREFRONTAL CORTEX; PROTO-ONCOGENE PROTEINS C-AKT; PSYCHOMOTOR PERFORMANCE; YOUNG ADULT;

EID: 84927697830     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291714000920     Document Type: Article

References (85)

1. Adams IB, Martin BR (1996). Cannabis: pharmacology and toxicology in animals and humans. Addiction 91, 1585-1614.
2. Aron AR, Durston S, Eagle DM, Logan GD, Stinear CM, Stuphorn V (2007). Converging evidence for a fronto-basal-ganglia network for inhibitory control of action and cognition. Journal of Neuroscience 27, 11860-11864.
3. Beaulieu JM, Gainetdinov RR, Caron MG (2007). The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends in Pharmacological Science 28, 166-172.
4. Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Prata D, Williams S, Brammer M, Collier DA, McGuire PK (2012a). Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of Δ-9-tetrahydrocannabinol on midbrain and striatal function. Molecular Psychiatry 17, 1152-1155.
5. 9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Archives of General Psychiatry 69, 27-36.
6. Bhattacharyya S, Crippa JA, Martin-Santos R, Winton-Brown T, Fusar-Poli P (2009a). Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Current Pharmaceutical Design 15, 2603-2614.
7. Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O'Carroll C, Allen P, Seal ML, Fletcher PC, Crippa JA, Giampietro V, Mechelli A, Atakan Z, McGuire P (2009b). Modulation of mediotemporal and ventrostriatal function in humans by Δ9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Archives of General Psychiatry 66, 442-451.
8. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O'Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK (2010). Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35, 764-774.
9. Blasi G, Napolitano F, Ursini G, Taurisano P, Romano R, Caforio G, Fazio L, Gelao B, Di Giorgio A, Iacovelli L, Sinibaldi L, Popolizio T, Usiello A, Bertolino A (2011). DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proceedings of the National Academy of Sciences USA 108, 1158-1163.
10. Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, Fraccaro V, Atakan Z, Martin-Santos R, O'Carroll C, Rubia K, McGuire PK (2008). Neural basis of Δ-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biological Psychiatry 64, 966-973.
11. 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34, 759-766.
12. Casey BJ, Trainor R, Orendi JL, Schubert AB, Nystrom LE, Giedd JN, Castellanos FX, Haxby JV, Noll DC, Cohen JD, Forman SD, Dahl RE, Rapoport JL (1997). A developmental functional MRI study of prefrontal activation during performance of a go/no-go task. Journal of Cognitive Neuroscience 9, 835-847.
13. Chamberlain SR, Sahakian BJ (2007). The neuropsychiatry of impulsivity. Current Opinion in Psychiatry 20, 255-261.
14. 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. European Journal of Pharmacology 190, 259-262.
15. 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berlin) 102, 156-162.
16. Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS (2004). Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. Journal of the American Medical Association 291, 2114-2121.
17. 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berlin) 164, 61-70.
18. Dale AM (1999). Optimal experimental design for event-related fMRI. Human Brain Mapping 8, 109-114.
19. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, Sirianni M, La Cascia C, Stilo SA, Marques TR, Handley R, Mondelli V, Dazzan P, Pariante C, David AS, Morgan C, Powell J, Murray RM (2012). Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biological Psychiatry 72, 811-816.
20. Duncan SC, Strycker LA, Duncan TE (1999). Exploring associations in developmental trends of adolescent substance use and risky sexual behavior in a high-risk population. Journal of Behavioral Medicine 22, 21-34.
21. Durston S, Thomas KM, Worden MS, Yang Y, Casey BJ (2002). The effect of preceding context on inhibition: an event-related fMRI study. Neuro Image 16, 449-453.
22. Eagle DM, Bari A, Robbins TW (2008). The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks. Psychopharmacology (Berlin) 199, 439-456.
23. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR (2001). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences USA 98, 6917-6922.
24. European Monitoring Centre for Drugs and Drug Addiction (2010). 2010 Annual report on the state of the drugs problem in Europe (http://www.emcdda.europa.eu/publications/annual-report/2010). Accessed 22 January 2014.
25. Fassbender C, Murphy K, Foxe JJ, Wylie GR, Javitt DC, Robertson IH, Garavan H (2004). A topography of executive functions and their interactions revealed by functional magnetic resonance imaging. Brain Research Cognitive Brain Research 20, 132-143.
26. Fergusson DM, Horwood LJ (1997). Early onset cannabis use and psychosocial adjustment in young adults. Addiction 92, 279-296.
27. Fillmore MT, Blackburn JS, Harrison EL (2008). Acute disinhibiting effects of alcohol as a factor in risky driving behavior. Drug and Alcohol Dependence 95, 97-106.
28. Freeman B, Smith N, Curtis C, Huckett L, Mill J, Craig IW (2003). DNA from buccal swabs recruited by mail: evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping. Behavior Genetics 33, 67-72.
29. French ED, Dillon K, Wu X (1997). Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8, 649-652.
30. Friedman AS, Glassman K, Terras BA (2001). Violent behavior as related to use of marijuana and other drugs. Journal of Addictive Diseases 20, 49-72.
31. Friedman AS, Kramer S, Kreisher C, Granick S (1996). The relationships of substance abuse to illegal and violent behavior, in a community sample of young adult African American men and women (gender differences). Journal of Substance Abuse 8, 379-402.
32. Garavan H, Ross TJ, Stein EA (1999). Right hemispheric dominance of inhibitory control: an event-related functional MRI study. Proceedings of the National Academy of Sciences USA 96, 8301-8306.
33. Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D'Incecco A, Smit EF, Falcone A, Burgers JA, Santoro A, Danesi R, Giaccone G, Tibaldi C (2010). Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Molecular Cancer Therapeutics 9, 581-593.
34. 1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochemical Journal 347, 369-373.
35. Hall W, Degenhardt L (2007). Prevalence and correlates of cannabis use in developed and developing countries. Current Opinion in Psychiatry 20, 393-397.
36. Hall W, Degenhardt L (2009). Adverse health effects of non-medical cannabis use. Lancet 374, 1383-1391.
37. Hall W, Solowij N (1998). Adverse effects of cannabis. Lancet 352, 1611-1616.
38. Hariri AR, Weinberger DR (2003). Imaging genomics. British Medical Bulletin 65, 259-270.
39. Harris SL, Gil G, Robins H, Hu W, Hirshfield K, Bond E, Bond G, Levine AJ (2005). Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proceedings of the National Academy of Sciences USA 102, 16297-16302.
40. Howes OD, Kapur S (2009). The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophrenia Bulletin 35, 549-562.
41. Kawashima R, Satoh K, Itoh H, Ono S, Furumoto S, Gotoh R, Koyama M, Yoshioka S, Takahashi T, Takahashi K, Yanagisawa T, Fukuda H (1996). Functional anatomy of GO/NO-GO discrimination and response selection - a PET study in man. Brain Research 728, 79-89.
42. Kingree JB, Betz H (2003). Risky sexual behavior in relation to marijuana and alcohol use among African-American, male adolescent detainees and their female partners. Drug and Alcohol Dependence 72, 197-203.
43. Krams M, Rushworth MF, Deiber MP, Frackowiak RS, Passingham RE (1998). The preparation, execution and suppression of copied movements in the human brain. Experimental Brain Research 120, 386-398.
44. Lai WS, Xu B, Westphal KG, Paterlini M, Olivier B, Pavlidis P, Karayiorgou M, Gogos JA (2006). Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proceedings of the National Academy of Sciences USA 103, 16906-16911.
45. Lane SD, Cherek DR, Tcheremissine OV, Lieving LM, Pietras CJ (2005). Acute marijuana effects on human risk taking. Neuropsychopharmacology 30, 800-809.
46. Li CS, Huang C, Constable RT, Sinha R (2006). Imaging response inhibition in a stop-signal task: neural correlates independent of signal monitoring and post-response processing. Journal of Neuroscience 26, 186-192.
47. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Davey Smith G (2004). Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 363, 1579-1588.
48. Martin-Santos R, Fagundo AB, Crippa JA, Atakan Z, Bhattacharyya S, Allen P, Fusar-Poli P, Borgwardt S, Seal M, Busatto GF, McGuire P (2010). Neuroimaging in cannabis use: a systematic review of the literature. Psychological Medicine 40, 383-398.
49. McDonald J, Schleifer L, Richards JB, de Wit H (2003). Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 28, 1356-1365.
50. McLellan AT, Luborsky L, Woody GE, O'Brien CP (1980). An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. Journal of Nervous and Mental Disease 168, 26-33.
51. Menon V, Adleman NE, White CD, Glover GH, Reiss AL (2001). Error-related brain activation during a Go/NoGo response inhibition task. Human Brain Mapping 12, 131-143.
52. National Centre for Natural Products Research (2009). Quarterly report: potency monitoring project: Report 104 (https://www.ncjrs.gov/pdffiles1/ondcp/mpmp-report-104.pdf). Accessed 22 January 2014.
53. Nelson HE (1982). National Adult Reading Test (NART): Test Manual. NFER-Nelson: Windsor.
54. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1980). Plasma Δ-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clinical Pharmacology and Therapeutics 28, 409-416.
55. Ozaita A, Puighermanal E, Maldonado R (2007). Regulation of PI3 K/Akt/GSK-3 pathway by cannabinoids in the brain. Journal of Neurochemistry 102, 1105-1114.
56. 9-tetrahydrocannabivarin. British Journal of Pharmacology 153, 199-215.
57. Pietilainen OP, Paunio T, Loukola A, Tuulio-Henriksson A, Kieseppa T, Thompson P, Toga AW, van Erp TG, Silventoinen K, Soronen P, Hennah W, Turunen JA, Wedenoja J, Palo OM, Silander K, Lonnqvist J, Kaprio J, Cannon TD, Peltonen L (2009). Association of AKT1 with verbal learning, verbal memory, and regional cortical gray matter density in twins. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 150B, 683-692.
58. 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. Journal of Forensic Sciences 53, 90-94.
59. Ramaekers JG, Berghaus G, van Laar M, Drummer OH (2004). Dose related risk of motor vehicle crashes after cannabis use. Drug and Alcohol Dependence 73, 109-119.
60. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR (2009). Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. Journal of Psychopharmacology 23, 266-277.
61. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR (2006). High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 31, 2296-2303.
62. Ramaekers JG, Robbe HW, O'Hanlon JF (2000). Marijuana, alcohol and actual driving performance. Human Psychopharmacology 15, 551-558.
63. Resnick MD, Bearman PS, Blum RW, Bauman KE, Harris KM, Jones J, Tabor J, Beuhring T, Sieving RE, Shew M, Ireland M, Bearinger LH, Udry JR (1997). Protecting adolescents from harm. Findings from the National Longitudinal Study on Adolescent Health. Journal of the American Medical Association 278, 823-832.
64. Rubia K, Lee F, Cleare AJ, Tunstall N, Fu CH, Brammer M, McGuire P (2005a). Tryptophan depletion reduces right inferior prefrontal activation during response inhibition in fast, event-related fMRI. Psychopharmacology (Berlin) 179, 791-803.
65. Rubia K, Russell T, Overmeyer S, Brammer MJ, Bullmore ET, Sharma T, Simmons A, Williams SC, Giampietro V, Andrew CM, Taylor E (2001). Mapping motor inhibition: conjunctive brain activations across different versions of go/no-go and stop tasks. Neuro Image 13, 250-261.
66. Rubia K, Smith AB, Brammer MJ, Toone B, Taylor E (2005b). Abnormal brain activation during inhibition and error detection in medication-naive adolescents with ADHD. American Journal of Psychiatry 162, 1067-1075.
67. Rubia K, Smith AB, Taylor E, Brammer M (2007). Linear age-correlated functional development of right inferior fronto-striato-cerebellar networks during response inhibition and anterior cingulate during error-related processes. Human Brain Mapping 28, 1163-1177.
68. Rubia K, Smith AB, Woolley J, Nosarti C, Heyman I, Taylor E, Brammer M (2006). Progressive increase of frontostriatal brain activation from childhood to adulthood during event-related tasks of cognitive control. Human Brain Mapping 27, 973-993.
69. Salvucci DD (2006). Modeling driver behavior in a cognitive architecture. Human Factors 48, 362-380.
70. 2 cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cellular Signalling 15, 851-859.
71. Schneider NG, Jarvik ME (1984). Time course of smoking withdrawal symptoms as a function of nicotine replacement. Psychopharmacology (Berlin) 82, 143-144.
72. Seamans JK, Yang CR (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Progress in Neurobiology 74, 1-58.
73. Skosnik PD, Spatz-Glenn L, Park S (2001). Cannabis use is associated with schizotypy and attentional disinhibition. Schizophrenia Research 48, 83-92.
74. 11C]-raclopride binding after THC challenge. Neuro Image 52, 1521-1527.
75. Tan HY, Chen AG, Chen Q, Browne LB, Verchinski B, Kolachana B, Zhang F, Apud J, Callicott JH, Mattay VS, Weinberger DR (2012). Epistatic interactions of AKT1 on human medial temporal lobe biology and pharmacogenetic implications. Molecular Psychiatry 17, 1007-1016.
76. Tan HY, Nicodemus KK, Chen Q, Li Z, Brooke JK, Honea R, Kolachana BS, Straub RE, Meyer-Lindenberg A, Sei Y, Mattay VS, Callicott JH, Weinberger DR (2008). Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. Journal of Clinical Investigation 118, 2200-2208.
77. Tanda G, Pontieri FE, Di Chiara G (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276, 2048-2050.
78. United Nations Office on Drugs and Crime (2010). World Drug Report 2010. United Nations Publication, Sales No. E.10.XI. 13 (http://www.unodc.org/documents/wdr/WDR-2010/World-Drug-Report-2010-lo-res.pdf). Accessed 22 January 2014.
79. van Winkel R, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2011a). Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Archives of General Psychiatry 68, 148-157.
80. van Winkel R, van Beveren NJ, Simons C (2011b). AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology 36, 2529-2537.
81. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG (2001). Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Research 107, 173-177.
82. Watts WD, Wright LS (1990). The relationship of alcohol, tobacco, marijuana, and other illegal drug use to delinquency among Mexican-American, black, and white adolescent males. Adolescence 25, 171-181.
83. 9-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana. Psychopharmacology (Berlin) 196, 119-131.
84. Weinstein A, Brickner O, Lerman H, Greemland M, Bloch M, Lester H, Chisin R, Sarne Y, Mechoulam R, Bar-Hamburger R, Freedman N, Even-Sapir E (2008b). A study investigating the acute dose-response effects of 13 mg and 17 mg Δ9-tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana. Journal of Psychopharmacology 22, 441-451.
85. White HR, Loeber R, Stouthamer-Loeber M, Farrington DP (1999). Developmental associations between substance use and violence. Development and Psychopathology 11, 785-803.